利格列汀与格列美脲对2型糖尿病患者主要不良心血管结局的影响:CAROLINA随机临床试验
CAROLINA是一项随机、双盲、活性对照、非劣效性试验,在43个国家607个中心纳入6042例糖化血红蛋白6.5%-8.5%、心血管风险升高的2型糖尿病成人患者。患者随机接受利格列汀5mg每日一次(n=3023)或格列美脲1-4mg每日一次(n=3010),在常规治疗基础上给药。主要终点为心血管死亡、非致死性心肌梗死或非致死性卒中的首次发生,利格列汀组11.8% vs 格列美脲组12.0%(HR 0.98,95.47%CI 0.84-1.14;非劣效P<.001),达到非劣效但未达优效(P=.76)。低血糖不良事件在利格列汀组10.6% vs 格列美脲组37.7%(HR 0.23,95%CI 0.21-0.26)。
要点
- 在心血管风险升高的相对早期2型糖尿病患者中,利格列汀5mg每日一次相比格列美脲1-4mg每日一次,中位随访6.3年的主要复合心血管结局非劣效(HR 0.98,95.47%CI 0.84-1.14)。
- 利格列汀组主要终点发生率为11.8%(356/3023),格列美脲组为12.0%(362/3010),达到非劣效但未达优效(P=.76)。
- 至少1次低血糖不良事件在利格列汀组为10.6%(320例),格列美脲组为37.7%(1132例),HR 0.23(95%CI 0.21-0.26)。
- 经裁定的急性胰腺炎在利格列汀组15例(0.5%),格列美脲组16例(0.5%)。
- 总体不良事件在利格列汀组为93.4%(2822例),格列美脲组为94.9%(2856例)。
适用人群与场景
- 成人2型糖尿病患者,糖化血红蛋白6.5%至8.5%,且有心血管风险升高。
- 心血管风险升高定义为:已确诊动脉粥样硬化性心血管疾病、多重心血管危险因素、年龄至少70岁,以及有微血管并发症证据。
- 研究在607个医院和初级保健中心开展,涉及43个国家。
处置流程与药物剂量
- 利格列汀5mg每日一次口服(n=3023),在常规治疗基础上给药。
- 格列美脲1至4mg每日一次口服(n=3010),在常规治疗基础上给药。
- 研究者被鼓励根据临床需要强化降糖治疗,主要方式是加用或调整二甲双胍、α-葡萄糖苷酶抑制剂、噻唑烷二酮类或胰岛素。
研究设计与关键结果
- 研究类型:随机、双盲、活性对照、非劣效性试验;样本量6042例随机化,6033例接受治疗并分析;在43个国家的607个医院和初级保健中心开展。
- 人群特征:平均年龄64.0岁,女性2414例(39.9%),平均糖化血红蛋白7.2%,糖尿病中位病程6.3年,42%有大血管疾病,59%曾接受二甲双胍单药治疗。
- 干预与对照:利格列汀5mg每日一次(n=3023) vs 格列美脲1-4mg每日一次(n=3010),在常规治疗基础上给药;中位随访6.3年。
- 主要终点(心血管死亡、非致死性心肌梗死或非致死性卒中的首次发生):利格列汀组356/3023(11.8%) vs 格列美脲组362/3010(12.0%),HR 0.98(95.47%CI 0.84-1.14),非劣效性P<.001,达到非劣效但未达优效(P=.76)。
- 不良事件:利格列汀组2822例(93.4%) vs 格列美脲组2856例(94.9%);经裁定的急性胰腺炎利格列汀组15例(0.5%) vs 格列美脲组16例(0.5%)。
- 至少1次低血糖不良事件:利格列汀组320例(10.6%) vs 格列美脲组1132例(37.7%),HR 0.23(95%CI 0.21-0.26)。
证据类型、等级与局限
- 证据类型:随机、双盲、活性对照、非劣效性试验。
- 非劣效性界值:利格列汀相对格列美脲的风险比双侧95.47%CI上限小于1.3。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在心血管风险升高、糖化血红蛋白6.5%-8.5%的相对早期2型糖尿病成人中,利格列汀相比格列美脲的主要复合心血管结局为非劣效(HR 0.98,95.47%CI 0.84-1.14)。
- 利格列汀组至少1次低血糖不良事件发生率低于格列美脲组(10.6% vs 37.7%,HR 0.23,95%CI 0.21-0.26)。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator.
OBJECTIVE: This trial assessed cardiovascular outcomes of linagliptin vs glimepiride (sulfonylurea) in patients with relatively early type 2 diabetes and risk factors for or established atherosclerotic cardiovascular disease.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, active-controlled, noninferiority trial, with participant screening from November 2010 to December 2012, conducted at 607 hospital and primary care sites in 43 countries involving 6042 participants. Adults with type 2 diabetes, glycated hemoglobin of 6.5% to 8.5%, and elevated cardiovascular risk were eligible for inclusion. Elevated cardiovascular risk was defined as documented atherosclerotic cardiovascular disease, multiple cardiovascular risk factors, aged at least 70 years, and evidence of microvascular complications. Follow-up ended in August 2018.
INTERVENTIONS: Patients were randomized to receive 5 mg of linagliptin once daily (n = 3023) or 1 to 4 mg of glimepiride once daily (n = 3010) in addition to usual care. Investigators were encouraged to intensify glycemic treatment, primarily by adding or adjusting metformin, α-glucosidase inhibitors, thiazolidinediones, or insulin, according to clinical need.
MAIN OUTCOMES AND MEASURES: The primary outcome was time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke with the aim to establish noninferiority of linagliptin vs glimepiride, defined by the upper limit of the 2-sided 95.47% CI for the hazard ratio (HR) of linagliptin relative to glimepiride of less than 1.3.
RESULTS: Of 6042 participants randomized, 6033 (mean age, 64.0 years; 2414 [39.9%] women; mean glycated hemoglobin, 7.2%; median duration of diabetes, 6.3 years; 42% with macrovascular disease; 59% had undergone metformin monotherapy) were treated and analyzed. The median duration of follow-up was 6.3 years. The primary outcome occurred in 356 of 3023 participants (11.8%) in the linagliptin group and 362 of 3010 (12.0%) in the glimepiride group (HR, 0.98 [95.47% CI, 0.84-1.14]; P < .001 for noninferiority), meeting the noninferiority criterion but not superiority (P = .76). Adverse events occurred in 2822 participants (93.4%) in the linagliptin group and 2856 (94.9%) in the glimepiride group, with 15 participants (0.5%) in the linagliptin group vs 16 (0.5%) in the glimepiride group with adjudicated-confirmed acute pancreatitis. At least 1 episode of hypoglycemic adverse events occurred in 320 (10.6%) participants in the linagliptin group and 1132 (37.7%) in the glimepiride group (HR, 0.23 [95% CI, 0.21-0.26]).
CONCLUSIONS AND RELEVANCE: Among adults with relatively early type 2 diabetes and elevated cardiovascular risk, the use of linagliptin compared with glimepiride over a median 6.3 years resulted in a noninferior risk of a composite cardiovascular outcome.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01243424.
参考来源
- Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019. PMID: 31536101. doi:10.1001/jama.2019.13772
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。